European EMA Grants Final Marketing Authorization for Pierre Fabre's Hemangiol, an Infantile Hemangioma Treatment
First Official Treatment for Infantile Hemangioma Approved
The European Medicines Agency (EMA) has granted final approval for Hemangiol (active ingredient: propranolol), an infantile hemangioma treatment developed by French pharmaceutical company Pierre Fabre. This approval was granted through the Pediatric Use Marketing Authorization (PUMA) scheme. It represents a significant clinical advancement as it provides the first officially approved, safe, and accessible oral treatment for this pediatric rare disease, addressing a significant unmet need. Previously, beta-blockers were prescribed off-label, leading to inconsistencies in treatment. This approval is expected to reduce confusion in clinical practice.
Proven Efficacy and Safety in Phase 2/3 Clinical Trials
The European approval of Hemangiol is based on data from a global Phase 2/3 clinical trial involving 460 infants. The results showed that in the group of infants receiving 3mg/kg daily for six months, the complete resolution rate of hemangioma was 60.4%, compared to 3.6% in the placebo group (p < 0.0001). This demonstrates a significant improvement in efficacy and provides a scientific basis for potentially replacing systemic corticosteroids, which were previously used but carried a higher risk of side effects. The development of a safe, liquid formulation for pediatric patients has also improved ease of administration and safety, contributing to the regulatory approval.
Shift in Standard of Care and Market Expansion
This EMA approval marks a turning point in the standard of care for infantile hemangioma. The global market for infantile hemangioma treatment is estimated at approximately $320 million in 2025. With the introduction of the first approved and safe treatment, market penetration is expected to increase rapidly. In particular, the mechanism of action of propranolol, a non-selective beta-adrenergic receptor antagonist, which inhibits the growth of blood vessels in newborns without affecting the heart and blood vessels, has been established, and research on related indications is also gaining momentum.
Changes in Competitive Landscape and Pierre Fabre's Market Position
Hemangiol is expected to solidify its market leadership through its first-mover advantage and initiate a technological competition with other beta-blocker-based drugs, such as atenolol. Atenolol has the advantage of being hydrophilic and not crossing the blood-brain barrier, which reduces the risk of side effects such as sleep disturbances. However, Hemangiol has already established a strong market position with its exclusive approval and extensive clinical data, creating a significant barrier to entry for competitors. Through this official entry into the European market, Pierre Fabre has completed its unique portfolio in the field of pediatric dermatology and secured long-term growth potential.
Pierre Fabre's Hemangiol approval in Europe, based on a 60.4% complete resolution rate demonstrated in Phase 2/3 trials, represents a short-term milestone in transforming the standard of care for infantile hemangioma from steroids to beta-blockers. From an investor's perspective, this approval allows for market leadership in the estimated $320 million global infantile hemangioma market in 2025, leveraging its Pediatric Use Marketing Authorization (PUMA) status for rapid market penetration and strong initial sales growth. Industry professionals anticipate that the supply chain for the first approved, safe, and oral liquid formulation will expand across Europe, rapidly absorbing the existing off-label market. From the perspective of researchers and competitors, comparative studies on safety and ease of administration with hydrophilic beta-blockers such as atenolol or topical timolol will be key determinants of long-term market share. This approval is considered a successful example of regulatory agencies incentivizing private sector clinical investment in pediatric rare diseases through the guarantee of exclusivity.
Source: EMA (ema)